Skip to main content
Top
Published in: Clinical Rheumatology 4/2010

01-04-2010 | Brief Report

Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity

Authors: Li Hui, Song Wuqi, Li Yang, Liu Yanhong, Bai Jing, Li Xiu, Mu Fengyun, Wang Yao, Zhang Fengshan, Su Liju, Zhang Fengmin

Published in: Clinical Rheumatology | Issue 4/2010

Login to get access

Abstract

This study was to evaluate the diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in northern Chinese Han patients with rheumatoid arthritis (RA) and its correlation with disease activity. Clinical data and serum samples were collected from 112 RA patients and 55 non-RA patients. Statistical analyses of the correlations among anti-CCP antibodies, other serological markers, and the RA patients’ clinical characteristics were performed using SPSS 11.5 software. Anti-CCP antibodies were detected in 77.7% of all RA patients and 80.4% of the RA patients with a disease duration of 3 years or less. The combined diagnosis using high titer anti-CCP antibodies (≥100 RU/ml) with a concomitant positive rheumatoid factor (RF) test exhibited the greatest diagnostic specificity; it achieved 87.9% for all RA patients and 90.1% for the patients with disease duration of three years or less. Moreover, anti-CCP antibodies showed medium correlations to the RA patient’s serum RF titer (r = 0.560, P < 0.001) and disease activity (DAS28 score; r = 0.404, P < 0.001). Compared with the patients with low anti-CCP antibody titers (<100 RU/ml), patients with high anti-CCP antibody titers showed higher RF titers, worse DAS28 scores, and severe morning stiffness (P < 0.01). This study suggests that anti-CCP antibodies can be used for RA diagnosis and disease activity evaluation for northern Han Chinese patients. A combined diagnosis using both high titers of anti-CCP antibodies (≥100 RU/ml) and a positive RF test markedly improves RA diagnostic specificity. Patients’ DAS28 scores rise and morning stiffness intensifies with increasing anti-CCP antibody titers.
Literature
1.
go back to reference Mediwake R, Isenberg DA, Schellekens GA et al (2001) Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 60:67–68CrossRefPubMed Mediwake R, Isenberg DA, Schellekens GA et al (2001) Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 60:67–68CrossRefPubMed
2.
go back to reference Silveira IG, Burlingame RW, von Mühlen CA et al (2007) Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 26:1883–1889CrossRefPubMed Silveira IG, Burlingame RW, von Mühlen CA et al (2007) Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 26:1883–1889CrossRefPubMed
3.
go back to reference Bukhari M, Thomson W, Naseem H et al (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 56:2929–2935CrossRefPubMed Bukhari M, Thomson W, Naseem H et al (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 56:2929–2935CrossRefPubMed
4.
go back to reference Yang CL, Zhou YR, Zhou F et al (2007) Diagnostic value of serum anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao 27:1277–1279PubMed Yang CL, Zhou YR, Zhou F et al (2007) Diagnostic value of serum anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao 27:1277–1279PubMed
5.
go back to reference Zeng X, Ai M, Tian X et al (2003) Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30:1451–1455PubMed Zeng X, Ai M, Tian X et al (2003) Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30:1451–1455PubMed
6.
go back to reference Wu Y, Xu Y, Sun Y et al (2008) Association between the serotonin 1A receptor C(-1019)G polymorphism and major depressive disorder in the northern Han ethnic group in China. Chin Med J 121:874–876PubMed Wu Y, Xu Y, Sun Y et al (2008) Association between the serotonin 1A receptor C(-1019)G polymorphism and major depressive disorder in the northern Han ethnic group in China. Chin Med J 121:874–876PubMed
8.
go back to reference Mimori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44:1112–1126CrossRef Mimori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44:1112–1126CrossRef
9.
go back to reference Kwok JS, Hui KH, Lee TL et al (2005) Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 34:359–366CrossRefPubMed Kwok JS, Hui KH, Lee TL et al (2005) Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 34:359–366CrossRefPubMed
10.
go back to reference Barnetche T, Constantin A, Cantagrel A et al (2008) New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples. Arthritis Res Ther 10:R26CrossRefPubMed Barnetche T, Constantin A, Cantagrel A et al (2008) New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples. Arthritis Res Ther 10:R26CrossRefPubMed
11.
go back to reference Senkpiehl I, Marget M, Wedler M et al (2005) HLA-DRB1 and anti-cyclic citrullinated peptide antibody production in rheumatoid arthritis. Int Arch Allergy Immunol 137:315–318CrossRefPubMed Senkpiehl I, Marget M, Wedler M et al (2005) HLA-DRB1 and anti-cyclic citrullinated peptide antibody production in rheumatoid arthritis. Int Arch Allergy Immunol 137:315–318CrossRefPubMed
12.
go back to reference van Gaalen FA, van Aken J, Huizinga TWJ et al (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121CrossRefPubMed van Gaalen FA, van Aken J, Huizinga TWJ et al (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121CrossRefPubMed
13.
go back to reference Fan LY, Zong M, Lu TB et al (2009) Association of the PADI4 gene polymorphism and HLA-DRB1 shared epitope alleles with rheumatoid arthritis. Zhong hua Yi Xue Yi Chuan Xue Za Zhi 26:57–61 Fan LY, Zong M, Lu TB et al (2009) Association of the PADI4 gene polymorphism and HLA-DRB1 shared epitope alleles with rheumatoid arthritis. Zhong hua Yi Xue Yi Chuan Xue Za Zhi 26:57–61
14.
go back to reference Xue Y, Zhang J, Chen YM et al (2008) The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis. Scand J Rheumatol 37:183–187CrossRefPubMed Xue Y, Zhang J, Chen YM et al (2008) The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis. Scand J Rheumatol 37:183–187CrossRefPubMed
Metadata
Title
Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity
Authors
Li Hui
Song Wuqi
Li Yang
Liu Yanhong
Bai Jing
Li Xiu
Mu Fengyun
Wang Yao
Zhang Fengshan
Su Liju
Zhang Fengmin
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1337-2

Other articles of this Issue 4/2010

Clinical Rheumatology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine